We deliver on Sourcing
En approvisionnement, nous travaillons pour vous
|
We deliver on Sourcing En approvisionnement, nous travaillons pour vous
|
|
NEWS
Sign up here for our monthly email updates (MailChimp)
SHOWCASE
|
DICHLOROACETATE SODIUM (DCA or Dichloroacetic acid Sodium salt) Purity (Assay > 99.0 %) CAS No: 2156-56-1 EC#: 218-461-3 Molecular Weight: 150.92 g/mole Chemical Formula: C2HCl2NaO2 Product Phase: Solid (Powder) Product Code: API10029 & API10067 The information below is solely for the technical guidance of prescribers and licensed dispensers of Sodium Dichloroacetate and must not be considered as a recommendation or endorsement for the use of the product. The information provided in this document may not be comprehensive. Active Ingredient Sodium Dichloroacetate Description of Product Sodium Dichloroacetate bulk powder, which may be used as an ingredient to produce other dosage forms (e.g. capsules) or may be divided into individual powders. Presentation A white plastic container containing 10g of Sodium Dichloroacetate. Storage Dry Powder: Store below 25°C in a dry place, out of direct sunlight. Replace lid tightly after use. Shelf Life Two years. Active Excipients None. Allergenic Information Sugar free and colour free, aspartame free. Therapeutic Indications Treatment of lactic acidosis in patients with defects in pyruvate dehydrogenase 1.Sodium Dichloroacetate may be used to treat lactic acidosis caused by other disorders such as lactic acidosis in sever malaria 2.Sodium Dichloroacetate has also been used in the treatment of other disorders of pyruvate metaboloism 3.Dosage Pyruvate dehydrogenase defects: By mouth neonates to adults: initially 12.5mg/kg four times daily, adjusted according to response to a maximum of 200mg/kg daily 1.Administration This is an unmixed powder intended to be used as an ingredient for extemporaneous preparations. The product may be divided into individual powders; the powder can be weighed into individual tablet bottles and dispensed to the patient. The individual powders may be mixed with water or sprinkled onto cold food and consumed immediately. Contraindications and Precautions Reversible polyneuropathy has been reported after chronic use, as has asymptomatic elevation of serum transaminases 2,3.Side-effects and Adverse Reactions Anxiolytic or sedative effects are common. Reduced urate clearance and elevated serum urate levels have been reported in patients with type 2 diabetes mellitus 2. Polyneuropathy on prolonged use, Abnormalities in oxalate metabolism. Concomitant metabolic acidosis1. Rise in glycerol in the CSF3.Mode of Action Dichloroacetic acid activates pyruvate dehydrogenase, a mitochondrial enzyme that catalyses metabolism of pyruvate and lactate which leads to reduced lactate levels, and it inhibits glycolysis 2.Pharmacokinetics No information available. Interactions with other Medications No information available. Pregnancy and Breastfeeding No information available. This information is solely for the technical guidance of prescribers and licensed dispensers of Sodium Dichloroacetate and must not be considered as a recommendation or endorsement for the use of the product. The information provided in this document may not be comprehensive.References: 1) J. Martin, British National Formulary for Children. London; BMJ Group, RPS Publishing.2008 2) S. Sweetman. Martindale the complete Drug Reference. London Pharmaceutical Press. 2009 3) D. Carson. Medicines for Children. 2 nd ed. London. RCPCH Publishing. 2003 |
|
A division of MAX Pharma Canada Inc. © Copyright 2009-2013. * Is a Trademark. All rights reserved. Terms of Use & Confidentiality. For problems or questions regarding this Web site contact us. Last updated: 03-Jan-2013. |